- Home
- PHAR vs EQBK Comparison
PHAR vs EQBK Comparison
Compare PHAR & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- EQBK
- Stock Information
- Founded
- PHAR 1988
- EQBK 2002
- Country
- PHAR Netherlands
- EQBK United States
- Employees
- PHAR N/A
- EQBK N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- EQBK Major Banks
- Sector
- PHAR Health Care
- EQBK Finance
- Exchange
- PHAR Nasdaq
- EQBK Nasdaq
- Market Cap
- PHAR 731.1M
- EQBK 696.9M
- IPO Year
- PHAR N/A
- EQBK 2015
- Fundamental
- Price
- PHAR $10.00
- EQBK $42.87
- Analyst Decision
- PHAR Strong Buy
- EQBK Buy
- Analyst Count
- PHAR 3
- EQBK 6
- Target Price
- PHAR $30.00
- EQBK $44.40
- AVG Volume (30 Days)
- PHAR 3.6K
- EQBK 83.2K
- Earning Date
- PHAR 07-31-2025
- EQBK 07-14-2025
- Dividend Yield
- PHAR N/A
- EQBK 1.40%
- EPS Growth
- PHAR N/A
- EQBK 543.37
- EPS
- PHAR N/A
- EQBK 3.93
- Revenue
- PHAR $320,708,000.00
- EQBK $224,743,000.00
- Revenue This Year
- PHAR $13.31
- EQBK $20.94
- Revenue Next Year
- PHAR $7.68
- EQBK $10.08
- P/E Ratio
- PHAR N/A
- EQBK $10.92
- Revenue Growth
- PHAR 24.13
- EQBK 56.39
- 52 Week Low
- PHAR $6.65
- EQBK $32.95
- 52 Week High
- PHAR $12.61
- EQBK $50.85
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- EQBK 63.84
- Support Level
- PHAR $9.99
- EQBK $43.00
- Resistance Level
- PHAR $10.59
- EQBK $44.32
- Average True Range (ATR)
- PHAR 0.35
- EQBK 1.13
- MACD
- PHAR -0.14
- EQBK 0.24
- Stochastic Oscillator
- PHAR 7.45
- EQBK 73.71
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.